Clinical Trials Directory

Trials / Sponsors / Denovo Biopharma LLC

Denovo Biopharma LLC

Industry · 17 registered clinical trials.

StatusTrialPhaseStarted
CompletedA Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TR
Treatment Resistant Depression
Phase 22022-06-29
CompletedA Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnos
Glioblastoma
Phase 32020-12-16
CompletedStudy to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Diffuse Large B-Cell Lymphoma
Phase 32018-03-20
WithdrawnA Study of LY2140023 in Healthy Participants
Healthy Participants
Phase 12012-08-01
CompletedA Study of LY2140023 in Healthy Participants
Healthy Participants
Phase 12012-07-01
CompletedA Study of LY2140023 in Healthy Participants
Healthy Volunteer Study
Phase 12012-06-01
CompletedA Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Sch
Schizophrenic Disorders
Phase 12012-06-01
CompletedA Study of LY2140023 in Healthy Males and Females
Healthy Volunteers
Phase 12012-04-01
CompletedA Physical Dependence Study in Schizophrenia
Schizophrenia
Phase 32011-11-01
CompletedA Study of LY2140023 in Hepatically-Impaired Participants
Hepatic Insufficiency
Phase 12011-11-01
CompletedA Study of Safety and Tolerability in Subjects With Schizophrenia
Schizophrenia
Phase 12011-05-01
TerminatedA Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
Schizophrenia
Phase 32011-04-01
TerminatedA Study of LY2140023 in Patients With Schizophrenia
Schizophrenia
Phase 32011-03-01
TerminatedA Study in Schizophrenic Patients
Schizophrenia
Phase 22010-05-01
CompletedA Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
Schizophrenia
Phase 22010-01-01
CompletedA Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
Schizophrenia
Phase 22009-03-01
CompletedStudy of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
Schizophrenia
Phase 22005-08-23